WAVE LIFE SCIENCES LTD (WVE)

SG9999014716 - Common Stock

12.9  -0.58 (-4.3%)

After market: 12.95 +0.05 (+0.39%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to WVE. WVE was compared to 191 industry peers in the Pharmaceuticals industry. While WVE seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, WVE is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year WVE has reported negative net income.
WVE had a negative operating cash flow in the past year.
In the past 5 years WVE always reported negative net income.
In the past 5 years WVE always reported negative operating cash flow.

1.2 Ratios

WVE's Return On Assets of -39.75% is in line compared to the rest of the industry. WVE outperforms 46.07% of its industry peers.
Looking at the Return On Equity, with a value of -95.32%, WVE is in line with its industry, outperforming 41.88% of the companies in the same industry.
Industry RankSector Rank
ROA -39.75%
ROE -95.32%
ROIC N/A
ROA(3y)-63.5%
ROA(5y)-62.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for WVE has been increased compared to 5 years ago.
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

WVE has an Altman-Z score of 0.42. This is a bad value and indicates that WVE is not financially healthy and even has some risk of bankruptcy.
WVE has a Altman-Z score (0.42) which is comparable to the rest of the industry.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC9.92%

2.3 Liquidity

A Current Ratio of 1.90 indicates that WVE should not have too much problems paying its short term obligations.
WVE has a worse Current ratio (1.90) than 60.21% of its industry peers.
A Quick Ratio of 1.90 indicates that WVE should not have too much problems paying its short term obligations.
WVE has a Quick ratio (1.90) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9

6

3. Growth

3.1 Past

The earnings per share for WVE have decreased strongly by -27.59% in the last year.
Looking at the last year, WVE shows a very negative growth in Revenue. The Revenue has decreased by -37.29% in the last year.
Measured over the past years, WVE shows a very strong growth in Revenue. The Revenue has been growing by 51.05% on average per year.
EPS 1Y (TTM)-27.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-771.43%
Revenue 1Y (TTM)-37.29%
Revenue growth 3Y78.03%
Revenue growth 5Y51.05%
Sales Q2Q%-115.6%

3.2 Future

Based on estimates for the next years, WVE will show a very strong growth in Earnings Per Share. The EPS will grow by 20.42% on average per year.
Based on estimates for the next years, WVE will show a very strong growth in Revenue. The Revenue will grow by 25.13% on average per year.
EPS Next Y-111.18%
EPS Next 2Y-39.23%
EPS Next 3Y-22.18%
EPS Next 5Y20.42%
Revenue Next Year-49.83%
Revenue Next 2Y-13.66%
Revenue Next 3Y0.93%
Revenue Next 5Y25.13%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WVE. In the last year negative earnings were reported.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

WVE's earnings are expected to decrease with -22.18% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.23%
EPS Next 3Y-22.18%

0

5. Dividend

5.1 Amount

WVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (12/27/2024, 8:00:02 PM)

After market: 12.95 +0.05 (+0.39%)

12.9

-0.58 (-4.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners64.7%
Inst Owner Change26.48%
Ins Owners0.52%
Ins Owner Change-0.59%
Market Cap1.97B
Analysts81.43
Price Target23.05 (78.68%)
Short Float %5.35%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42%
Min EPS beat(2)-64.24%
Max EPS beat(2)-19.77%
EPS beat(4)1
Avg EPS beat(4)-15.14%
Min EPS beat(4)-64.24%
Max EPS beat(4)34.48%
EPS beat(8)3
Avg EPS beat(8)-57.91%
EPS beat(12)4
Avg EPS beat(12)-40.74%
EPS beat(16)6
Avg EPS beat(16)-29.32%
Revenue beat(2)0
Avg Revenue beat(2)-82.36%
Min Revenue beat(2)-144.85%
Max Revenue beat(2)-19.88%
Revenue beat(4)1
Avg Revenue beat(4)-41.44%
Min Revenue beat(4)-144.85%
Max Revenue beat(4)44.87%
Revenue beat(8)3
Avg Revenue beat(8)-3.13%
Revenue beat(12)3
Avg Revenue beat(12)-29.64%
Revenue beat(16)4
Avg Revenue beat(16)-17.73%
PT rev (1m)1.35%
PT rev (3m)63.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)39.05%
Revenue NY rev (1m)-9.97%
Revenue NY rev (3m)-25.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.7
P/FCF N/A
P/OCF N/A
P/B 13.16
P/tB 13.16
EV/EBITDA N/A
EPS(TTM)-1.11
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.35
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.75%
ROE -95.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.5%
ROA(5y)-62.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.66%
Cap/Sales 2.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z 0.42
F-Score4
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)16.83%
Cap/Depr(5y)23.73%
Cap/Sales(3y)13.2%
Cap/Sales(5y)14.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-771.43%
EPS Next Y-111.18%
EPS Next 2Y-39.23%
EPS Next 3Y-22.18%
EPS Next 5Y20.42%
Revenue 1Y (TTM)-37.29%
Revenue growth 3Y78.03%
Revenue growth 5Y51.05%
Sales Q2Q%-115.6%
Revenue Next Year-49.83%
Revenue Next 2Y-13.66%
Revenue Next 3Y0.93%
Revenue Next 5Y25.13%
EBIT growth 1Y-63.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.25%
EBIT Next 3Y-36.52%
EBIT Next 5YN/A
FCF growth 1Y-38.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.72%
OCF growth 3YN/A
OCF growth 5YN/A